Given that many lung adenocarcinomas lacking EGFR/RAS/RAF mutations also displayed significant MAPK activation (Cancer Genome Atlas Research, 2014), it is reasonable to predict that there are additional, still undetected MAPK pathway regulators. The gene discussed is EGFR; the disease is lung adenocarcinoma.